CABS Posters

For presentation during the Poster Reception 18:00-19:00 on Sunday 1 July and manned at the following times:

Odd numbers on Monday 2 July 13:20-14:00
Even numbers on Tuesday 3 July 13:20-14:00

P1
Abstract withdrawn

P2
Refilling of bony myeloma lytic lesions mediated by total therapy 4 treatment
Maurizio Zangari (Little Rock, USA)

P3
Bone seeking MMP-2 inhibitors can prevent bone metastatic breast cancer
Marilena Tauro (Tampa, USA)

P4
Preclinical testing of trail therapeutics for sarcoma
Zakareya Gamie (Newcastle upon Tyne, UK))

P5
Humanized mouse models of triple-negative and triple-positive breast cancer bone metastasis for preclinical validation of novel immuno-oncology therapies
Mari I Suominen (Turku, Finland)

P6
Preventing and repairing myeloma bone disease by combining conventional anti-resorptive treatment with a novel bone anabolic treatment
Jenny Down (Sheffield, UK)

P7
Inhibiting IL-1B signalling increases therapeutic efficacy of doxorubicin and zoledronic acid in immunocompetent models of mammary cancer bone metastases.
Penelope Ottewell (Sheffield, UK)

P8
Tumour derived IL-1B Induces differential tumour promoting mechanisms in breast cancer bone metastasis
Penelope Ottewell (Sheffield, UK)

P9
Interleukin-34 as a potential therapeutic target for the treatment of osteosarcoma
Kristina Schiavone (Sheffield, UK)

P10
Combination of capecitabine and radium-223 for patients with breast cancer and bone metastases: Results of the CARBON trial phase IB initial safety stage
Janet Brown (Sheffield, UK)

P11
Enrichment and detection of tumor cells in novel models of breast cancer bone colonization
Miranda Sowder (Nashville, USA)

P12
Panobinostat significantly prevents osteosarcoma progression and metastasis
Jeremy McGuire (Tampa, USA)

P13
BMP4 gene therapy inhibits myeloma tumor growth, but has a negative impact on bone
Marita Westhrin (Trondheim, Norway)

P14
Abstract withdrawn

P15
Myeloid Derived Suppressor Cells promote Multiple Myeloma cell survival by AMPK activation
Kim De Veirman (Brussels, Belgium)

P16
The role of serum vitamin-D and bone turnover markers in prognosis of bone metastasis and prediction of benefit from adjuvant zoledronic acid in patients with early breast cancer.
Janet Brown (Sheffield, UK)

P17
Lysyl oxidase promotes survival and outgrowth of cancer cells in the bone marrow, enabling bone metastasis formation.
Caroline Reynaud (Lyon, France)

P18
Guidelines for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from a UK expert group.
Janet Brown (Sheffield, UK)

P19
Computational modeling of macrophage polarization dynamics in skeletal malignancies. An integrated in silico and in vivo approach
Chen Hao Lo (Tampa, USA)

P20
Abstract withdrawn

P21
Host-derived matrix metalloproteinase-13 contributes to the progression of multiple myeloma
Chen Hao Lo (Tampa, USA)

P22
Imaging upregulated cell surface proteins, altered tumor metabolism and structural bone changes in multiple myeloma
Monica Shokeen (St Louis, USA)

P23
The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease
Masahiro Hiasa (Tokushima, USA)

P24
Human osteoclasts generated from different individuals show a highly variable sensitivity to zoledronic acid in vitro – this sensitivity relates to in vivo characteristics of each individual
Kent Søe (Vejle, Denmark)

P25
Investigating the osteoblast-breast cancer cell interaction at early stages of bone metastasis
Marie-Therese Haider (Hamburg, Germany)

P26
Defining the role of P2X7 receptor in the dormant population of prostate cancer cells
Hector Arredondo (Sheffield, UK)

P27
Characteristics of the stromal cells in the premetastatic and hematopoietic niches
Inaam Nakchbandi (Heidelberg, Germany)

P28
Learning from osteoblasts how to fight cancer
Inaam Nakchbandi (Heidelberg, Germany)

P29
Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth.
Georgia Stewart (Sheffield, UK)

P30
FACS-based isolation of primary and metastatic osteosarcoma cells in mice: a new tool to allow downstream molecular analysis and target identification
Charlotte Palmer (Cambridge, UK)

P31
Abstract withdrawn

P32
Abstract withdrawn

P33
Inhibition of p62-ZZ Domain-Mediated Signaling in Myeloma Bone Disease Induces Osteoblast Differentiation and Overcomes Bortezomib Resistance.
Silvia Marino (Indianapolis, USA)

P34
The Role of Receptor Activity Modifying Protein 1 in Prostate Cancer.
Jessica Warrington (Sheffield, UK)

P35
Investigating the influence of bone marrow adipocytes on breast cancer metastasis
Nadia Halidi (Oxford, UK)

P36
Leukaemia inhibitory factor: a novel mediator of prostate cancer bone metastasis?
Christina Turner (Oxford, UK)

P37
Myeloma cell down-regulation of adiponectin in bone marrow adipose tissue promotes growth and survival via TNF-alpha
Emma Morris (Oxford, UK)

P38
3D Perfusion Bioreactor Model of Tumor-Induced Bone Disease
Joseph Vanderburgh (Nashville, USA)

P39
Unravelling the metabolic relationship in the prostate cancer-bone microenvironment; a novel role for the pentose phosphate pathway
Jessica Whitburn (Oxford, UK)

P40
Effect of tumour-derived extracellular vesicles on the molecular profile of osteoblasts and on endothelial functions
Riccardo Paone (L'Aquila, Italy)

P41
Abstract withdrawn

P42
LKB1 deficiency exhibits vulnerable mitochondrial defects by rapamycin on urothelial carcinoma cells
Young Mi Whang (Seoul, Republic of Korea)

P43
Pretreatment with metformin alters the host microenvironment to increase myeloma tumour burden and bone disease in vivo
Beatriz Gamez (Oxford, UK)

P44
Marrow Adipose Tissue is Associated with Regions of Hypoxia During Metastatic Colonization of the Bone
Colleen Wu (Durham, USA)

P45
Transcriptional regulators of oncogenesis and of osteoblastic differentiation revealed by microRNA profiling of osteosarcoma cell lines and primary human osteoblasts
Brendan Norman (Liverpool, UK)

P46
Vascular cell adhesion molecule (VCAM) 1 and α4β1 integrin interactions regulate myeloid-derived suppressor cells (MDSC) mobilization from the bone marrow of tumor hosts
Serk In Park (Seoul, Republic of Korea)

P47
Modelling the human bone-tumour niche ex vivo
Srinivasa Rao (Oxford, UK)

P48
Contribution of marrow adipocytes to destructively lytic behavior of metastatic kidney tumors in bone
Mackenzie Herroon (Detroit, USA)

P49
Combined administration of a novel small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis
Ryan Bishop (Sheffield, UK)

P50
Altering glycosphingolipid composition to improve multiple myeloma bone disease
Houfu Leng (Oxford, UK)

P51
Transcriptomic profiling of the in vivo myeloma bone-lining niche identifies BMP signalling as a therapeutic target for bone disease
Sarah Gooding (Oxford, UK)

P52
Bone-specific activation of a dietary polyphenol inhibiting TGFß-dependent breast cancer bone metastases
Janet L Funk (Tucson, USA)

P53
Development of Novel Nanomedicines for Treatment of Primary and Metastatic Prostate Cancer
Omer Aydin (Istanbul, Turkey)

P54
Mechanical signals retain musculoskeletal endpoints while suppressing adiposity in a murine model of complete estrogen deprivation
Gabriel M Pagnotti (Indianapolis, USA)

P55
Mechanical signals retain musculoskeletal endpoints while suppressing adiposity in a murine model of complete estrogen deprivation.
Gabriel M Pagnotti (Indianapolis, USA)

P56
Bone-sialoprotein (BSP), Dickkopf-1 (DKK1) and CXCR4 as potential biomarkers of breast cancer metastasis to bone: Analysis within the AZURE (BIG 01/04) study of adjuvant zoledronic acid.
Steven Wood (Sheffield, UK)

P57
Functionalized Rare earth-doped Nanoparticles for Breast Cancer Detection and Potential Bone-targeting Contrast Agents
Patricia Juárez (Ensenada, Mexico)

P58
An agent based model of the bone remodelling process and its disruption by multiple myeloma.
Curtis Palasiuk (Sheffield, UK)